Laboratory manifestations of COVID-19 associated with hemostatic abnormalities

Main Article Content

Ahmed Elhadi Elsadig May Mohammed Ali Alfatih Aboalbasher Yousif

Main Article Content


Hemostatic abnormalities had been reported in COVID-19 patients, which may include disseminated intravascular coagulation (DIC), hypercoagulability, and alterations in platelets parameters. Articles that investigate the alterations of hemostatic abnormalities during the COVID-19 disease (2020-2021) and their predictive value of disease outcome have been thoroughly reviewed. Among the reviewed articles, thrombocytopenia is observed in 5.0-41.7% of COVID-19 patients, which is related to disease severity. Moreover, other platelets parameters, including Platelets/lymphocytes ratio (PLR), Mean platelets volume (MPV), and aggregation, may also be affected. On the other hand, findings of coagulation tests such as D dimer; fibrinogen, Antithrombin (AT), and Fibrin degradation products (FDP) are significantly elevated in COVID-19 patients, while in a single study, most of the patients had positive Lupus anticoagulants (LA) and normal protein C (PC). In the same perspective, these alterations showed significant correlations with disease severity. Overall, hemostatic laboratory markers are significant predictors of COVID-19 disease outcome as indicated by the increased risk of venous and arterial thrombotic events, especially in ICU patients.


Article Details

How to Cite
Elsadig A, Ali M, Yousif A. Laboratory manifestations of COVID-19 associated with hemostatic abnormalities. jidhealth [Internet]. 18Aug.2021 [cited 23Jan.2022];4(3):423-7. Available from: